8月27日，Veeva Systems盘中上涨13.63%，报283.615美元/股，成交额1.0亿美元。
消息面上，公司发布财年Q2业绩，调整后每股收益2.35美元，超市场预期的2.22美元约5.86%，同比增长18.09%；营收9.28亿美元，超预期的9.05亿美元约2.5%。全年EPS指引上调至约9.21美元，高于市场预期的9.06美元；全年营收指引36.82亿至36.87亿美元，亦超出市场预期。
此外，财报前公司接连签下Biogen、Regeneron及Eli Lilly三大药企为Vault CRM全球客户，目前已锁定全球前20大药企中的13家，进一步巩固生命科学CRM龙头地位。多家机构上调目标价，Baird将目标价由260美元升至300美元，Guggenheim和Stifel分别上调至276美元和275美元，均维持买入评级。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.